Lumbrokinase is a group of fibrinolytic enzymes extracted from earthworms (particularly Lumbricus rubellus and Eisenia fetida) that has been used in traditional Chinese medicine for thousands of years. It works primarily by breaking down fibrin and preventing blood clot formation through direct fibrinolytic activity, independent of plasminogen. Clinically, it is used to support cardiovascular health, treat thrombotic conditions, and has shown potential benefits in reducing ischemia-reperfusion injury in various organs.

Overview

Lumbrokinase is a complex of fibrinolytic enzymes isolated from the earthworm Lumbricus rubellus (and related species), with a long history of use in Traditional Chinese Medicine where dried earthworm preparations ("Di Long") have been prescribed for cardiovascular and cerebrovascular conditions for centuries. The enzyme complex contains at least six serine and metalloprotease isoforms with complementary mechanisms of fibrinolytic action: some directly degrade fibrin (similar to plasmin), while others activate tissue plasminogen activator (t-PA) and urokinase plasminogen activator (u-PA), converting inactive plasminogen to the active fibrinolytic enzyme plasmin. This dual mechanism — direct fibrinolysis plus plasminogen activation — gives lumbrokinase a more comprehensive thrombolytic profile than single-mechanism enzymes like nattokinase, which primarily activates the plasminogen pathway.

Clinical research on lumbrokinase has been most extensive in China and Southeast Asia, where it has been studied in ischemic stroke, coronary artery disease, deep vein thrombosis, and peripheral vascular disease. Studies demonstrate reductions in fibrinogen levels (the fibrin precursor), D-dimer (a fibrin degradation marker), blood viscosity, and platelet aggregation following oral lumbrokinase supplementation. A notable advantage is its oral bioavailability — the enzymes survive gastric acid degradation and are absorbed intact from the intestinal tract, maintaining fibrinolytic activity in systemic circulation. Dosing in clinical studies typically ranges from 400,000–2,000,000 IU daily in divided doses, taken on an empty stomach to maximize absorption and prevent enzymatic interaction with food proteins.

Lumbrokinase occupies an important position in integrative cardiovascular and hypercoagulability protocols. It is frequently used alongside nattokinase for combined fibrinolytic coverage, serrapeptase for systemic proteolytic support, omega-3 fatty acids for anti-inflammatory vascular protection, and CoQ10 for cardiac energy metabolism. However, its potent fibrinolytic activity necessitates caution: lumbrokinase should not be combined with anticoagulant medications (warfarin, heparin, direct oral anticoagulants) or antiplatelet drugs without medical supervision, and must be discontinued 1–2 weeks before surgical procedures. Individuals with bleeding disorders, active hemorrhage, or recent stroke should avoid lumbrokinase entirely. When used appropriately under clinical guidance, it represents one of the most potent orally bioavailable fibrinolytic enzymes available as a dietary supplement.

Mechanism of Action

Lumbrokinase is a complex of six fibrinolytic serine protease isoenzymes extracted from the earthworm Lumbricus rubellus (also known as Eisenia fetida in some preparations). These enzymes possess a unique dual mechanism of fibrinolytic action. Several isoenzymes directly cleave fibrin polymers by hydrolyzing specific peptide bonds in the fibrin network, physically degrading the structural scaffold of blood clots. This direct fibrinolytic activity distinguishes lumbrokinase from many other thrombolytic agents that rely solely on plasminogen activation.

Complementing its direct action, other lumbrokinase isoenzymes function as plasminogen activators, converting the inactive zymogen plasminogen into the active serine protease plasmin. Plasmin then degrades fibrin through its natural fibrinolytic activity, amplifying the thrombolytic effect. This dual mechanism — combining direct fibrin degradation with plasminogen activation — provides robust and efficient clot dissolution. Lumbrokinase also reduces circulating fibrinogen levels through direct proteolysis, which decreases blood viscosity, reduces erythrocyte aggregation, and limits the substrate available for new thrombus formation.

Lumbrokinase demonstrates additional cardiovascular benefits through inhibition of platelet aggregation. The enzymes interfere with thromboxane A2-mediated platelet activation and reduce platelet adhesion to damaged endothelium. Unlike pharmaceutical thrombolytics such as streptokinase or alteplase, lumbrokinase has demonstrated oral bioavailability, with the enzymes surviving gastric transit (particularly in enteric-coated formulations) and being absorbed intact from the intestine. Its relatively selective action on fibrin over fibrinogen at therapeutic doses suggests a lower bleeding risk compared to non-selective fibrinolytic agents.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Lumbrokinase

Common Side Effects

• Lumbrokinase is a group of fibrinolytic enzymes derived from earthworms (Lumbricus rubellus), used as a thrombolytic/fibrinolytic supplement
• Generally well-tolerated at standard doses (40–120 mg/day or 400,000–1,200,000 IU/day)
• Gastrointestinal symptoms: nausea, diarrhea, abdominal discomfort, and bloating
• Mild headache reported in some users
• Unpleasant taste or odor from earthworm-derived preparations
• Minor bruising or prolonged bleeding from minor cuts due to fibrinolytic activity

Serious Adverse Effects

• Hemorrhagic events: as a potent fibrinolytic enzyme, lumbrokinase degrades fibrin and may cause significant bleeding — epistaxis, gingival bleeding, gastrointestinal hemorrhage, hematuria, or intracranial hemorrhage in extreme cases
• Allergic reactions: anaphylaxis possible in individuals with sensitivities to earthworm proteins or invertebrate-derived products
• Hemorrhagic stroke risk: theoretical but serious concern when combined with other anticoagulants or in individuals with cerebrovascular disease
• Excessive anticoagulation manifesting as persistent or unexplained bruising, petechiae, or prolonged wound healing
• No established reversal agent for lumbrokinase-induced bleeding (unlike heparin or warfarin)

Contraindications

• Active bleeding from any source (GI hemorrhage, intracranial bleed, trauma)
• Hemorrhagic stroke history or high hemorrhagic risk cerebrovascular disease
• Severe thrombocytopenia (platelet count <50,000/μL)
• Upcoming surgery or invasive procedures — discontinue at least 2 weeks prior
• Known allergy to earthworm-derived products
• Active peptic ulcer disease
• Uncontrolled severe hypertension (increases hemorrhagic stroke risk)

Drug Interactions

• Anticoagulants (warfarin, heparin, enoxaparin, rivaroxaban, apixaban): MAJOR INTERACTION — additive anticoagulant/fibrinolytic activity dramatically increases bleeding risk; concomitant use requires medical supervision and monitoring
• Antiplatelet agents (aspirin, clopidogrel, ticagrelor, prasugrel): additive bleeding risk; avoid combination or use under close monitoring
• NSAIDs (ibuprofen, naproxen, diclofenac): increased GI bleeding risk from dual anticoagulant and mucosal-damaging effects
• Thrombolytic agents (alteplase, tenecteplase): absolute contraindication for concurrent use
• Other fibrinolytic supplements (nattokinase, serrapeptase): additive fibrinolytic activity; avoid stacking multiple fibrinolytic enzymes without medical guidance
• Fish oil/omega-3 fatty acids: mild additive antiplatelet effects; monitor for bruising

Population-Specific Considerations

• Pregnancy: contraindicated — fibrinolytic activity may impair placental hemostasis and increase hemorrhagic risk during pregnancy and delivery; no human reproductive safety data
• Lactation: no data on excretion into breast milk; avoid during breastfeeding due to unknown risk to infant
• Children: no pediatric safety or dosing data; not recommended for use in individuals under 18
• Elderly: may benefit from fibrinolytic activity for cardiovascular health, but increased baseline bleeding risk with age; start at lower doses; ensure regular monitoring of bleeding signs and coagulation parameters
• Pre-surgical patients: mandatory discontinuation at least 14 days before any surgical or dental procedure; inform all healthcare providers of use

Pharmacokinetic Profile